Literature DB >> 11960016

Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.

Holly H Nguyen1, Vianney Jayasinha, Bing Xia, Kwame Hoyte, Paul T Martin.   

Abstract

Duchenne muscular dystrophy (DMD) is a congenital X-linked myopathy caused by lack of dystrophin protein expression. In DMD, the expression of many dystrophin-associated proteins (DAPs) is reduced along the sarcolemmal membrane, but the same proteins remain concentrated at the neuromuscular junction where utrophin, a dystrophin homologue, is expressed [Matsumura, K., Ervasti, J. M., Ohlendieck, K., Kahl, K. D. & Campbell, K. (1992) Nature (London) 360, 588-591]. This outcome has led to the concept that ectopic expression of a "synaptic scaffold" of DAPs and utrophin along myofibers might compensate for the molecular defects in DMD. Here we show that transgenic overexpression of the synaptic CT GalNAc transferase in the skeletal muscles of mdx animals (mdx/CT) increases the expression of utrophin and many DAPs, including dystroglycans, sarcoglycans, and dystrobrevins, along myofibers. Protein expression of utrophin and DAPs was equal to or above that of wild-type mice. In addition, alpha-dystroglycan was glycosylated with the CT carbohydrate antigen in mdx/CT but not in mdx muscles. mdx/CT mice have little or no evidence of muscular dystrophy by several standard measures; Serum creatine kinase levels, percentage of centrally located myofiber nuclei, and variance in myofiber diameter in mdx/CT muscles were dramatically reduced compared with mdx mice. These data suggest that ectopic expression of the CT GalNAc transferase creates a functional dystrophin-related complex along myofibers in the absence of dystrophin and should be considered as a target for therapeutic intervention in DMD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960016      PMCID: PMC122819          DOI: 10.1073/pnas.082613599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.

Authors:  J T Den Dunnen; P M Grootscholten; E Bakker; L A Blonden; H B Ginjaar; M C Wapenaar; H M van Paassen; C van Broeckhoven; P L Pearson; G J van Ommen
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

2.  Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression.

Authors:  Bing Xia; Kwame Hoyte; Anja Kammesheidt; Tom Deerinck; Mark Ellisman; Paul T Martin
Journal:  Dev Biol       Date:  2002-02-01       Impact factor: 3.582

3.  Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface.

Authors:  E Bonilla; C E Samitt; A F Miranda; A P Hays; G Salviati; S DiMauro; L M Kunkel; E P Hoffman; L P Rowland
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

4.  Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle.

Authors:  K Ohlendieck; J M Ervasti; K Matsumura; S D Kahl; C J Leveille; K P Campbell
Journal:  Neuron       Date:  1991-09       Impact factor: 17.173

5.  Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy.

Authors:  G Karpati; S Carpenter; S Prescott
Journal:  Muscle Nerve       Date:  1988-08       Impact factor: 3.217

6.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

7.  Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide.

Authors:  K Arahata; S Ishiura; T Ishiguro; T Tsukahara; Y Suhara; C Eguchi; T Ishihara; I Nonaka; E Ozawa; H Sugita
Journal:  Nature       Date:  1988-06-30       Impact factor: 49.962

8.  Membrane organization of the dystrophin-glycoprotein complex.

Authors:  J M Ervasti; K P Campbell
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

9.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.

Authors:  A H Beggs; E P Hoffman; J R Snyder; K Arahata; L Specht; F Shapiro; C Angelini; H Sugita; L M Kunkel
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

10.  A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.

Authors:  M Wehling; M J Spencer; J G Tidball
Journal:  J Cell Biol       Date:  2001-10-01       Impact factor: 10.539

View more
  62 in total

Review 1.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

2.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

3.  Deletion of Pofut1 in Mouse Skeletal Myofibers Induces Muscle Aging-Related Phenotypes in cis and in trans.

Authors:  Deborah A Zygmunt; Neha Singhal; Mi-Lyang Kim; Megan L Cramer; Kelly E Crowe; Rui Xu; Ying Jia; Jessica Adair; Isabel Martinez-Pena Y Valenzuela; Mohammed Akaaboune; Peter White; Paulus M Janssen; Paul T Martin
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

Review 4.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

5.  Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.

Authors:  Louis G Chicoine; Louise R Rodino-Klapac; Guohong Shao; Rui Xu; William G Bremer; Marybeth Camboni; Bethannie Golden; Chrystal L Montgomery; Kimberly Shontz; Kristin N Heller; Danielle A Griffin; Sarah Lewis; Brian D Coley; Christopher M Walker; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Paul T Martin
Journal:  Mol Ther       Date:  2013-10-22       Impact factor: 11.454

6.  ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice.

Authors:  Pauliina Kronqvist; Nobuko Kawaguchi; Reidar Albrechtsen; Xiufeng Xu; Henrik Daa Schrøder; Behzad Moghadaszadeh; Finn Cilius Nielsen; Camilla Fröhlich; Eva Engvall; Ulla M Wewer
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 7.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

8.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

9.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

10.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Authors:  Jung Hae Yoon; Kumaran Chandrasekharan; Rui Xu; Matthew Glass; Neha Singhal; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2009-05-12       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.